Bimekizumab-bkzx
Bimekizumab-Bkzx is a bispecific monoclonal antibody designed to treat inflammatory conditions by targeting and neutralizing two key cytokines (IL-17A and IL-17F) involved in the inflammatory response. It is used in patients with moderate to severe autoimmune diseases where these cytokines play a significant role in driving inflammation and symptoms.
A biologic medication that reduces inflammation by blocking IL-17A and IL-17F cytokines, used for autoimmune conditions like psoriasis and arthritis.
Key facts at a glance
- RxNorm
- 2668080
- Generic
- Bimekizumab-Bkzx
- Class
- pin-variant
- Brands
- Bimzelx
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Primarily used for moderate to severe plaque psoriasis, and may also be indicated for psoriatic arthritis and axial spondyloarthritis. Treatment is typically considered for patients who have not responded adequately to conventional systemic therapies.
As a bispecific monoclonal antibody, Bimekizumab-Bkzx simultaneously binds to and neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two pro-inflammatory cytokines. By blocking both pathways, it provides more comprehensive inhibition of the inflammatory cascade compared to targeting IL-17A alone.
As an injectable biologic, administration should be supervised by a healthcare provider experienced in treating autoimmune conditions. Patients should be screened for infections, particularly tuberculosis, before starting therapy. Common side effects may include oral candidiasis, upper respiratory infections, and injection site reactions. Long-term safety monitoring is required during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy